This mornings posts are almost funny if not sad. Given the proformance of management in the past I understand the frustration though.

Focusing on COVID versus BoM2 is only logical for a company with limited funds. This trial once it actually starts dosing can be fully recruited in less than a week, maybe even less than a day. It's an open label trial. Early results will be available within about a month of starting dosing, maybe within 2 weeks. Merck's drug that sent their market cap up about $20 billion had a 53% effectiveness and could have some serious side effects in DNA alterations.

APB has recently come off a PIII trial of 4200 patient years with a pretty good safety record. All be it those patients did not have COVID but there were no significant long term problems. APB did stop or significantly reduce the cytokine storm which as it turns out is important for COVID patients along with reducing inflammation. We also saw that the kidneys responded well to the drug as well as the brain vessels.

Consequent to BoM the Australian study showed that mice dosed with APB had a response rate of over 70%. That study also showed that heart cells were being repaired after just a couple hours after dosing. Now to boot, that study was written up in the Cell, the top rated molecular science report available today.

What they did find for APB in the University of Nebraska trial was that the lung cells in the COVID mice that were being repaired within 3 hours of dosing starting.

In addition to the above there was a PHA study that showed positive effect as well.

Add a little political twist now. Since Canada's federal election just last month we now have a Liberal MP here in Calgary that wants to make a name for himself and the Liberal party in general. It has now been 13 months since the federal government has said they will give us a grant of $3 million which we have not seen one cent of. This fellow could get an enormous amount of positive exposure for being part of bringing a successful home grown COVID therapeutic to the for.

Now look at what is being done by the company. It's not perfect by any means but it is being done. Market awareness in the video clip done in that hotel room, another done with Eversana, yet another short clip on BNN and now these virtual conferences. These are just market awareness efforts. The news release the other day about the ethics board approval was just a heads up that we are about to begin dosing.

Some current shareholders are so tarnished that no matter what the opportunity that lays ahead there will be little or no shine at all that will come through. There is no question at all that your thoughts and the reasons for them have validity. We can only hope that this time might be a little different. From what I'm seeing as stated above, the approach this time does look different.

To recap now, we have this little Cdn biotech that has a drug that could be repurposed for COVID that has just come off a 4200 patient year trial with a good safety record. This drug stops or significantly reduces the cytokine storm and reduces inflammation, has a positive effect on heart, lung, kidney and liver cells and a positive effect on brain vessels. In a recent PI study it showed that it had a positive effect on over 70% of the COVID mice that were dosed with APB. Their nearest competitor so far has shown a 53% effectiveness with potential safety issues and their market cap went up $20 billion when the results were revealed. 

If APB works the same way in this COVID trial as it did in BoM, the PAH trial, the Australian trial, the University of Nebraska trial, the kidney study, and the brain study we may have the only drug available that will not only help current COVID patients but also long COVID patients which is about 25% of all people that contract COVID. To boot, if pricing is similar to what it would be for cardio patients we would come in at less than half of what Merck's inferior product is priced at.

IMO if there is any success in this COVID trial it will morph into an extended trial and end up being the boggy that every pharma will have to one up to be in the lead.

Just my two cents worth.

tada